MorphoSys Stock

MorphoSys P/FCF

Delisted

The P/FCF (Price-to-Free-Cash-Flow Ratio) of MorphoSys (MOR.DE) as of Aug 16, 2026 is -8.55. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -6.93 — a change of 23.41% (lower).

P/FCF

-8.55

YoY

23.41%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of MorphoSys is 2026 -8.55 . P/FCF (Price-to-Free-Cash-Flow Ratio) of MorphoSys was 2025 -6.93 . It decreases by 23.41% lower compared to the previous year.
Access this data via the Eulerpool API

MorphoSys Stock analysis

What does MorphoSys do? MorphoSys AG is a biotech company based in Planegg near Munich, Germany, founded in 1992. The company specializes in the discovery and development of therapeutic antibodies and operates worldwide. MorphoSys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MorphoSys stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of MorphoSys is -8.55 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of MorphoSys changed from -6.93 to -8.55, representing a 23.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) MorphoSys since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s MorphoSys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — MorphoSys

All Key Metrics — MorphoSys